Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib for severe mast cell activation syndrome (MCAS)
2024-515193-27-00Phase 2Completed
- Sponsor
- AB Science
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of masitinib in Mast Cell Activation Syndrome (MCAS) (3 arms), sponsored by AB Science. Primary endpoint: Primary confirmed response at 50% at week 24. Started Sep 2024; status: completed.
02
Drugs
masitinib
03
Conditions
Mast Cell Activation Syndrome (MCAS)
Beyond the preview
Go deeper on 2024-515193-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515193-27-00.